公开(公告)号：US20240324599A1

公开(公告)日：2024-10-03

申请号：US18615771

申请日：2024-03-25

申请人： Spogen Biotech Inc.

发明人： Brian M. Thompson ,  Andrew M. Mutka ,  Alejandro Tovar-Mendez ,  Erica D. Mueller

IPC分类号： A01N63/22 ,  A01N63/50 ,  A01P5/00 ,  A01P7/04 ,  A01P9/00 ,  A01P21/00 ,  C12N1/00 ,  C12N9/20 ,  C12N9/42 ,  C12N9/50

CPC分类号： A01N63/22 ,  A01N63/50 ,  A01P5/00 ,  A01P7/04 ,  A01P9/00 ,  A01P21/00 ,  C12N1/00 ,  C12N9/20 ,  C12N9/2442 ,  C12N9/50

摘要： Isolated enzymes exhibiting insecticidal, nematicidal, or pesticidal activity, and recombinant microorganisms expressing said enzymes are provided as well as methods of using the same to protect a plant from a pathogen or pest, improve plant health, or improve plant growth are provided.

公开(公告)号：US12084666B2

公开(公告)日：2024-09-10

申请号：US16608146

申请日：2018-04-27

申请人： STOWERS INSTITUTE FOR MEDICAL RESEARCH ,  FRED HUTCHINSON CANCER CENTER

发明人： Sarah E. Zanders ,  Nicole Nuckolls ,  Maria Angelical Bravo Nunez ,  Harmit Singh Malik

IPC分类号： C12N15/81 ,  C07K14/39 ,  C12N1/00

CPC分类号： C12N15/815 ,  C07K14/39 ,  C12N1/00 ,  C12N2800/00 ,  C12N2840/007

摘要： The present disclosure provides, inter alia, meiotic drive genes derived from chromosome 3 of the fission yeasts Schizosaccharomyces kambucha and S. pombe and orthologs thereof. In certain embodiments, compositions, methods, and kits are provided for biasing organisms to express such genes and, optionally, to co-express one or more genes of interest in such organisms.

公开(公告)号：US12024703B2

公开(公告)日：2024-07-02

申请号：US18183262

申请日：2023-03-14

申请人： The Texas A&M University System

发明人： Carlos F. Gonzalez ,  Stephen J. Ahern ,  Mayukh Das ,  Ryland F. Young, III ,  Tushar Suvra Bhowmick

IPC分类号： C12N1/00 ,  A01N63/40 ,  C12N7/00 ,  C12N15/82 ,  C12R1/91

CPC分类号： C12N1/00 ,  A01N63/40 ,  C12N7/00 ,  C12N15/8281 ,  C12N2795/10121 ,  C12N2795/10131 ,  C12N2795/10221 ,  C12N2795/10231 ,  C12N2795/10321 ,  C12N2795/10331 ,  C12R2001/91

摘要： Methods and compositions are provided for preventing or reducing symptoms or disease associated with Xylella fastidiosa or Xanthomonas axonopodis in a plant. The invention provides novel bacteriophages virulent to Xylella fastidiosa or Xanthomonas axonopodis, including XfaMija and XfaMijo, and further provides methods for treating or preventing Pierce's Disease or Citrus Canker in plants.

公开(公告)号：US11993798B2

公开(公告)日：2024-05-28

申请号：US17743469

申请日：2022-05-13

申请人： ACON-HOLDING INC.

发明人： Pao-Hung Lin

IPC分类号： C12P1/04 ,  C01B19/00 ,  C01G1/02 ,  C01G1/12 ,  C01G41/00 ,  C01G41/02 ,  C09K5/14 ,  C12P3/00 ,  B82Y5/00 ,  C12N1/00 ,  C12R1/00

CPC分类号： C12P1/04 ,  C01B19/007 ,  C01G1/02 ,  C01G1/12 ,  C01G41/00 ,  C01G41/02 ,  C09K5/14 ,  C12P3/00 ,  B82Y5/00 ,  C01P2002/82 ,  C01P2004/03 ,  C01P2004/34 ,  C12N1/00 ,  C12R2001/00

摘要： A method for manufacturing bacterially induced crystal particle includes culturing bacteria in a culture medium including a carbon source and a raw metal material including a transition metal, so that the bacteria induce a raw metal material to undergo a reduction-oxidation reaction; isolating a wet powder material from the culture medium; and drying the wet powder material to obtain a powder material. The powder material includes at least one bacterially induced crystal particle.

公开(公告)号：US11945853B2

公开(公告)日：2024-04-02

申请号：US17839815

申请日：2022-06-14

申请人： UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

发明人： Qiuhong Li ,  Mohan Raizada

IPC分类号： C07K14/575 ,  A61K35/00 ,  A61K35/74 ,  A61K35/741 ,  A61K35/747 ,  A61K45/06 ,  A61K48/00 ,  A61P3/00 ,  A61P3/10 ,  A61P9/12 ,  A61P27/02 ,  A61P29/00 ,  C07K7/14 ,  C07K14/195 ,  C07K14/28 ,  C07K14/47 ,  C07K19/00 ,  C12N1/00 ,  C12N9/48

CPC分类号： C07K14/575 ,  A61K35/74 ,  A61K35/741 ,  A61K35/747 ,  A61K45/06 ,  A61P3/00 ,  A61P3/10 ,  A61P9/12 ,  A61P27/02 ,  A61P29/00 ,  C07K7/14 ,  C07K14/195 ,  C07K14/28 ,  C07K14/47 ,  C07K19/00 ,  C12N1/00 ,  C12N9/485 ,  A61K2035/115 ,  A61K48/00 ,  C07K2319/02 ,  C07K2319/50 ,  C07K2319/60

摘要： Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.

公开(公告)号：US20240092955A1

公开(公告)日：2024-03-21

申请号：US18511083

申请日：2023-11-16

申请人： NISSAN CHEMICAL CORPORATION

发明人： Kohei SUZUKI ,  Yoshiomi HIROI ,  Natsuki ABE

IPC分类号： C08F220/34 ,  C08F2/06 ,  C08F2/44 ,  C08F220/06 ,  C08J5/18 ,  C12M1/12 ,  C12N1/00

CPC分类号： C08F220/34 ,  C08F2/06 ,  C08F2/44 ,  C08F220/06 ,  C08J5/18 ,  C12M25/02 ,  C12N1/00

摘要： The invention provides a method for producing a polymer used as a base film for cell culture which comprises (i) preparing a mixture containing (a) a monomer of formula (I):




wherein Ua1 and Ua2 each independently represent a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms, Ra1 represents a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms, and Ra2 represents a linear or branched alkylene group having 1 to 5 carbon atoms, (b) a radical polymerization initiator, and (c) an organic solvent, and (ii) preparing a polymer by raising a temperature of the mixture under stirring to polymerize the monomer. The invention also provides methods of producing a base film for cell culture and a cell culture container.

公开(公告)号：US20240052294A1

公开(公告)日：2024-02-15

申请号：US18273166

申请日：2021-02-08

申请人： c-square bioscience GmbH

发明人： Gerald Kraetschmer

IPC分类号： C12N1/00 ,  C12M1/12 ,  C12M1/34 ,  C12M1/36

CPC分类号： C12N1/00 ,  C12M37/00 ,  C12M41/36 ,  C12M41/48 ,  C12M41/26 ,  C12M41/32

摘要： Device and method for controlling a content of microorganisms in a liquid, the device carrying out the method and comprising:



a measuring unit for measuring the microorganism content,
a control unit which, in order to achieve a predefined microorganism content, determines a dosage of a biocide on the basis of the measured microorganism content using a model with at least one parameter,
a supply unit, which supplies the biocide to the liquid in the dosage determined by the control unit, and
a computing unit, which calculates the at least one parameter from a recording of the microorganism content measured by the measuring unit over at least one past time interval and the amount of biocide supplied in this time interval.

公开(公告)号：US11898190B2

公开(公告)日：2024-02-13

申请号：US17401894

申请日：2021-08-13

申请人： KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION ,  KONAN GAKUEN ,  NIPPON SUISAN KAISHA, LTD.

发明人： Yuji Okita ,  Makoto Ito ,  Rie Hamaguchi ,  Hatsumi Goda ,  Seiya Mochinaga ,  Daisuke Honda

IPC分类号： C12P7/6432 ,  C12N15/09 ,  C12P7/64 ,  C12P1/00 ,  C12N15/79 ,  C12P7/6427 ,  C12P7/6472 ,  C12P19/34 ,  C12N1/00 ,  C12N1/12 ,  C12R1/00 ,  C12R1/89 ,  C10G3/00 ,  C12N15/52

CPC分类号： C12P7/6432 ,  C12N15/09 ,  C12N15/79 ,  C12P1/00 ,  C12P7/64 ,  C12P7/6427 ,  C12P7/6472 ,  C12P19/34 ,  C10G3/00 ,  C12N1/00 ,  C12N1/125 ,  C12N15/52 ,  C12R2001/00 ,  C12R2001/89

摘要： A method for producing a microbial oil includes steps of: genetically modifying a labyrinthulid by disrupting and/or silencing a gene, or by transforming another gene in addition to the disruption and/or gene silencing of the gene, and culturing the labyrinthulid, such that a fatty acid composition accumulated in the labyrinthulid comprises an increased EPA content; and collecting the microbial oil having the increased EPA content from the labyrinthulid. The labyrinthulid before the modification is selected from (A) a labyrinthulid belonging to the genus Parietichytrium or genus Schizochytrium and having very weak or no activity of producing PUFAs via a PUFA-PKS pathway; and (B) a labyrinthulid belonging to the genus Thraustochytrium in which a host PUFA-PKS gene is disrupted or silenced to a very weak level. The increased EPA content is preferably not less than 11.5% of a total fatty acid composition.

公开(公告)号：US11890307B2

公开(公告)日：2024-02-06

申请号：US18179801

申请日：2023-03-07

申请人： Finch Therapeutics Holdings LLC

发明人： Thomas Julius Borody

IPC分类号： A61K35/74 ,  A61K35/24 ,  A61M3/02 ,  C12N1/20 ,  C12N1/00 ,  A61P1/12 ,  A61M39/00 ,  A61J1/14 ,  A61K35/741 ,  A61K9/48 ,  A61K35/742 ,  A61K35/00 ,  A61M31/00 ,  A61B10/00 ,  A61M39/24 ,  A61M5/142

CPC分类号： A61K35/74 ,  A61J1/1468 ,  A61K9/4891 ,  A61K35/24 ,  A61K35/741 ,  A61K35/742 ,  A61M3/02 ,  A61M3/0204 ,  A61M39/00 ,  A61P1/12 ,  C12N1/00 ,  C12N1/20 ,  A61B10/0038 ,  A61K9/4875 ,  A61K2035/115 ,  A61M5/142 ,  A61M31/00 ,  A61M39/24

摘要： The present disclosure provides compositions, enema products, and enema delivery systems used for gastric, gastrointestinal and/or colonic treatments; and methods for making and using them. Methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.

公开(公告)号：US11801267B2

公开(公告)日：2023-10-31

申请号：US16106723

申请日：2018-08-21

申请人： METCELA INC.

发明人： Takahiro Iwamiya ,  Katsuhisa Matsuura

IPC分类号： A61K35/33 ,  A61K38/17 ,  C12N5/077 ,  C12N1/00 ,  C12N5/10

CPC分类号： A61K35/33 ,  A61K38/1774 ,  C12N1/00 ,  C12N5/0656 ,  C12N5/0657 ,  C12N5/10 ,  C12N2501/58 ,  C12N2502/1323 ,  C12N2502/1329

摘要： The purpose of the present invention is to provide a cardiac cell culture material which specifically acts on cardiac cells. In addition, another purpose of the present invention is to provide artificial organ material obtained by culturing by using said cardiac cell culture material, and a method for producing the same. Thus, provided is a cardiac cell culture, wherein functional cardiac tissue is favorably built by using a cardiac cell culture material containing VCAM-1.